The study concludes that adding Jemperli to PtCh and Zejula provides a statistically significant but clinically modest PFS benefit, with no improvement in OS for newly diagnosed advanced OC patients.

To expand Jemperli’s success beyond endometrial cancer ·Clinical Trials Arena GlobalData Healthcare Tue, Jun 3, 2025, 9:30 AM4 min read ...

Jemperli – the seventh approved drug in the PD-1/PD-L1 inhibitor class – was acquired by GSK as part of its $5.1 billion takeover of Tesaro along with PARP inhibitor Zejula (niraparib ...

GSK’s PD-1 inhibitor Jemperli has been cleared for use by the NHS as a first-line treatment for a specific type of endometrial cancer, making it an option for around 580 women across England ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Emerging PD-1 and PD-L1 Inhibitors therapies such as - CTX-8371, CA 327, RC-98, AUR-106, INBRX 105, Tomivosertib, CX-072, IBI 323, Jemperli, BCD-100, TECENTRIQ, Opdivo, KEYTRUDA, and others are ...

The FIRST/ENGOT-OV44 trial evaluated adding dostarlimab (Jemperli, GSK) to platinum-based chemotherapy and niraparib (Zejula, GSK) maintenance, with or without bevacizumab (Avastin, Genentech), in ...

In the segment, while products like Nucala and Dovato are key top-line drivers, new long-acting HIV medicines, Cabenuva and Apretude, as well as new oncology drugs Jemperli and Ojjaara, are also ...

GSK acquired both Jemperli (co-developed with AnaptysBio) and Zejula through its $5.31 billion acquisition of Tesaro in 2019. After the FDA’s accelerated approval in 2021 for patients with mismatch ...